A carregar...
Pharmacokinetics of conivaptan use in patients with severe hepatic impairment
PURPOSE: Conivaptan is an intravenous dual V(1A)/V(2) vasopressin antagonist approved for the treatment of euvolemic and hypervolemic hyponatremia. Earlier studies showed that patients with moderate liver disease could be safely treated with conivaptan by reducing the dose by 50%, whereas patients w...
Na minha lista:
| Publicado no: | Drug Des Devel Ther |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5315214/ https://ncbi.nlm.nih.gov/pubmed/28243060 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S125459 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|